Description
Product Characteristics: Amylin or islet amyloid polypeptide (IAPP) is produced in the pancreas beta cells and co-released with insulin. The amino acid sequence shows great homology with calcitonin gene related peptide (CGRP). Amylin has been shown to reverse insulin inhibition of hepatic gluconeogenesis and to inhibit muscle uptake of glucose.
Polyclonal anti-Amylin was obtained by immunizing a rabbit with human amylin.
Target Information: Selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism